Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 771-776

  Gronchi, A ^a   Bui, B N ^b   Bonvalot, S ^c   Pilotti, S ^a   Ferrari, S ^d   Hohenberger, P ^e   Hohl, R J ^f   Demetri, G D ^g   Le cesne, A ^c   Lardelli, P ^h   Perez I ^h   Nieto, A ^h   Tercero, J C ^h   Alfaro, V ^h   Tamborini, E ^a   Blay, J Y ⁱ  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUT BERGONIÉ   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF IOWA   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h PHARMAMAR S A   (Spain)

ⁱ CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; Liposarcoma; Neoadjuvant; Soft tissue sarcoma; Surgery

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DEXAMETHASONE; TRABECTEDIN;

ADIPOSE TISSUE CELL; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CLASSIFICATION; CANCER REGRESSION; CELL MATURATION; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIPOBLAST; LIVER FAILURE; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VASCULARIZATION; VOMITING;

EID: 84857530639     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr265     Document Type: Article

References (24)

1. Orvieto E, Furlanetto A, Laurino L, Dei Tos AP. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol 2001; 18: 267-273.
2. Hohenberger P, Wysocki WM. Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: which treatment to choose? Oncologist 2008; 13: 175-186.
3. Eilber FC, Eilber FR, Eckardt J et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004; 240: 686-695; discussion 695-697.
4. Patel SR, Burgess MA, Plager C et al. Myxoid liposarcoma. Experience with chemotherapy. Cancer 1994; 74: 1265-1269.
5. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595-602.
6. Grosso F, Demetri GD, Blay JY et al. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I. 24: 9511.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
8. Frapolli R, Tamborini E, Virdis E et al. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacological features of human tumors. Clin Cancer Res 2010; 16: 4958-4967.
9. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010; 9: 2157-2163.
10. Germano G, Frapolli R, Simone M et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010; 70: 2235-2244.
11. Forni C, Minuzzo M, Virdis E et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009; 8: 449-457.
12. Grosso F, Forni C, Frapolli R et al. Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. J Clin Oncol 2007; (Meeting Abstracts) 25: 10000.
13. Hollebecque A, Adenis A, Taieb S et al. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Invest New Drugs 2009; 28: 529-530.
14. Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23: 5484-5492.
15. Grosso F, Sanfilippo R, Virdis E et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009; 20: 1439-1444.
16. Casali PG, Sanfilippo R, D'Incalci M. Trabectedin therapy for sarcomas. Curr Opin Oncol 2010; 22: 342-346.
17. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
18. Ganjoo KN, Patel SR. Trabectedin: an anticancer drug from the sea. Expert Opin Pharmacother 2009; 10: 2735-2743.
19. R; ET-743): a drug of marine origin for soft-tissue sarcoma. Hosp Pharm Eur 2008; 37: 19-23.
20. Schoffski P, Dumez H, Wolter P et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008; 9: 1609-1618.
21. Zelek L, Yovine A, Brain E et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006; 94: 1610-1614.
22. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007; 67: 2257-2276.
23. Cioffi A, LeCesne A, Blay J-Y et al. Trabectedin phase II clinical trials: pooled analysis of safety in patients with solid tumors. J Clin Oncol 2009; 27: (Abstr) e13510.
24. Del Campo JM, Roszak A, Bidzinski M et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20: 1794-1802.